The German developer of a vaccine against Koronavirus plans to attract $245 million for IPO

The German biotechnological company CureVac, among other engaged development vaccines against Koronavirus, declared on Monday, August 10 that it plans to attract to $245 million during IPO. Placement has to take place at the American technological exchange NASDAQ. That company plans IPO, it became known in July, now she declared a price band of placement — from $14 to $16 for an action — and number of stocks which it plans to place at the exchange — 13,3 million actions with an option for underwriters on purchase 2 million more actions at IPO price within a month, that is in...